Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 1, 1997, Pages 95-100

  Den Hollander, Jan G ^a   Horrevorts, Alphonsus M ^b   Van Goor, Mary Lou P J ^c   Verbrugh, Henri A ^a,c   Mouton, Johan W ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JULIANA CHILDREN S HOSPITAL   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; CELL KILLING; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0031038395     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.1.95     Document Type: Article

References (32)

1. Barclay, M. L., E. J. Begg, S. T. Chambers, and D. R. Boswell. 1995. Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro. Antimicrob. Agents Chemother. 39:132-136.
2. Berenbaum, M. C. 1978. A method for testing synergy with any number of agents. J. Infect. Dis. 137:122-130.
3. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1985. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 28:64-68.
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamase and its correlation molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
5. Chandrasekar, P. H., L. R. Crane, and E. J. Bailey. 1987. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J. Antimicrob. Chemother. 19:321-329.
6. Chin, N. X., and H. C. Neu. 1983. Synergy of azlocillin with aminoglycosides. J. Antimicrob. Chemother. 11(Suppl. B):33-38.
7. Elion, G. B., S. Singer, and G. H. Hitchings. 1953. Antagonists of nucleic acid derivates. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
8. Fantin, B., and C. Carbon. 1992. In vivo antibiotic synergism: contribution of animal models. Antimicrob. Agents Chemother. 36:907-912.
9. GraphPad Software, Inc. 1990. Instat 2 program manual. GraphPad Software, Inc., San Diego, Calif.
10. Guggenblicher, J. P., F. Allerberger, M. P. Dierich, R. Schmitzberger, and E. Semenitz. 1988. Spaced administration of antibiotic combinations to eliminate pseudomonas from sputum in cystic fibrosis. Lancet ii:749-750.
11. Hallander, K. O., K. Dornbusch, L. Gezelius, K. Jacobson, and I. Karlsson. 1982. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob. Agents Chemother. 22:743-752.
12. Horrevorts, A. M., C. M. de Ridder, M. C. Poot, M. J. A. de Jonge, J. E. Degener, G. Dzoljic-Danilovic, M. F. Michel, and K. F. Kerrebijn. 1987. Checkerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index. J. Antimicrob. Chemother. 19:119-125.
13. Horrevorts, A. M., M. F. Michel, and K. F. Kerrebijn. 1987. Antibiotic interaction: interpretation of fractional inhibitory and fractional bactericidal concentration indices. Eur. J. Clin. Microbiol. 4:502-503.
14. Johnson, D. E., and B. Thompson. 1986. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Am. J. Med. 80(Suppl. 5C):53-58.
15. Johnson, D. E., B. Thompson, and F. M. Calia. 1985. Comparative activities of piperacillin, ceftazidime, and amikacin alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. Antimicrob. Agents Chemother. 27:735-739.
16. Klastersky, J., and S. H. Zinner. 1982. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev. Infect. Dis. 4:294-301.
17. Klastersky, J., R. Cappel, and D. Daneau. 1972. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob. Agents Chemother. 2:470-475.
18. König, P., J. P. Guggenblicher, E. Semenitz, and W. Foisner. 1986. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. Chemotherapy 32:44-58.
19. Lumish, R. M., and C. W. Norden. 1976. Therapy of neutropenic rats infected with Pseudomonas aeruginosa. J. Infect. Dis. 133:538-547.
20. McGrath, B. J., K. C. Lamp, and M. J. Rybak. 1993. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Antimicrob. Agents Chemother. 37:1931-1937.
21. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
22. Mouton, J. W., J. G. den Hollander, and A. M. Horrevorts. 1993. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Antimicrob. Chemother. 31:919-926.
23. Mouton, J. W., A. M. Horrevorts, P. H. G. Mulder, E. P. Prens, and M. F. Michel. 1990. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusion in healthy volunteers. Antimicrob. Agents Chemother. 34:2307-2311.
24. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. Norden, C. W., H. Wentzel, and E. Keleti. 1979. Comparison of techniques for measurement of in vitro synergism. J. Infect. Dis. 140:692-733.
26. Reyes, M. P., F. Smith, and A. M. Lerner. 1984. Studies of in vitro synergy between several beta-lactam and aminoglycoside antibiotics against endocarditis strains of Pseudomonas aeruginosa. J. Infect. 8:110-117.
27. Scott, R. E., and H. G. Robson. 1976. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats. Antimicrob. Agents Chemother. 10:646-651.
28. Stratton, C. W., and R. C. Cooksey. 1991. Susceptibility tests: special tests, p. 1153-1166. In A. Balows (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
29. Van de Klundert, J. A. M., M. H. van Gestel, E. van Doorn, and R. P. Mouton. 1986. Disc diffusion test for the determination of semi-quantitative substrate profiles of β-lactamases. J. Antimicrob. Chemother. 17:471-479.
30. Van de Klundert, J. A. M., J. S. Vliegenthart, E. van Doorn, G. P. A. Bongaerts, L. Molendijk, and R. P. Mouton. 1984. A simple method for identification of aminoglycoside-modifying enzymes. J. Antimicrob. Chemother. 14:339-348.
31. Vergères, P., and J. Blaser. 1992. Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection. J. Infect. Dis. 165:281-289.
32. Zinner, S. H., J. Blaser, B. B. Stone, and M. C. Groner. 1985. Use of an in-vitro kinetic model to study antibiotic combinations. J. Antimicrob. Chemother. 15(Suppl. A):221-226.